Benzbromarone is a pro-uric acid excretory drug used in the treatment of gout and hyperuricemia patients to lower blood uric acid. Gastrointestinal discomfort and abnormal liver and kidney function are the adverse effects of benzbromarone. Benzbromarone is one of the commonly used drugs for the treatment of gout and hyperuricemia. Benzbromarone is a pro-uric acid excretory drug, which can reduce the concentration of uric acid in blood by inhibiting the reabsorption of uric acid in the renal tubules. Gastrointestinal discomfort and abnormal liver and kidney function are the adverse effects of benzbromarone. Patients taking benzbromarone may experience gastrointestinal discomfort such as nausea, vomiting, abdominal distention, diarrhea, etc. Individual patients may experience elevation of transaminases after taking non-benzbromarone, which can be recovered after stopping the drug. Because benzbromarone promotes uric acid excretion by inhibiting the reabsorption of uric acid in the renal tubules, it is not recommended for patients with moderate to severe renal impairment and may aggravate renal impairment if taken. Although it has certain adverse reactions, it can be used safely as long as the physician is fully consulted before use, any adverse reactions are observed during use, and the blood count and liver and kidney function are reviewed regularly.